Diploma PLC (LON:DPLM – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the seven analysts that are presently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is GBX 5,605.71.
A number of equities research analysts have issued reports on the company. JPMorgan Chase & Co. restated a “neutral” rating and set a GBX 4,440 price objective on shares of Diploma in a research report on Wednesday, August 6th. Royal Bank Of Canada raised Diploma to an “outperform” rating and boosted their target price for the company from GBX 4,500 to GBX 6,000 in a research report on Friday, October 3rd. Peel Hunt restated a “buy” rating and set a GBX 6,150 price target on shares of Diploma in a report on Tuesday. Berenberg Bank reaffirmed a “buy” rating and set a GBX 6,350 price objective on shares of Diploma in a research note on Wednesday. Finally, Jefferies Financial Group boosted their price objective on shares of Diploma from GBX 4,500 to GBX 5,200 and gave the company a “hold” rating in a research report on Thursday, September 11th.
View Our Latest Stock Report on DPLM
Diploma Stock Up 0.8%
Insider Buying and Selling
In other news, insider Geraldine Huse purchased 750 shares of the business’s stock in a transaction that occurred on Wednesday, November 19th. The shares were bought at an average cost of GBX 3,997 per share, for a total transaction of £29,977.50. Insiders own 1.13% of the company’s stock.
About Diploma
Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.
Further Reading
- Five stocks we like better than Diploma
- How to invest in marijuana stocks in 7 steps
- A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves
- Why Are Stock Sectors Important to Successful Investing?
- 12 Analysts Just Raised CrowdStrike Targets—Here’s What They See Coming
- 3 Stocks to Consider Buying in October
- Palo Alto Networks Stock Just Pulled Back—Is This a Prime Buy Zone?
Receive News & Ratings for Diploma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diploma and related companies with MarketBeat.com's FREE daily email newsletter.
